Adicet Bio, Inc.(ACET US)

$3.99-0.296.78%Ext:$4.42+0.4310.85%(Market Closed · 00:00:05 UTC)

Summary

Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.

Website

www.adicetbio.com

Location

Boston, MA, US

Phone650 503 9095

Employees102

CEOChen Schor

Sector

Health Care

Industry

Pharmaceuticals

IPO DateJan 26, 2018

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

Latest Documents

Mentions in Filings

… OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc. and Lomond Therapeutics Holdings, Inc., each a public biopharmaceutical company, as well as several private companies. Dr. Gordon previously served on the boards of directors of several public companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 404 ---
Rallybio CorpAdicet Bio, Inc.·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·15 Oct
… OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc. and Lomond Therapeutics Holdings, Inc., each a public biopharmaceutical company, as well as several private companies. Dr. Gordon previously served on the boards of directors of several public companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 404 ---
Rallybio CorpAdicet Bio, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·14 Oct
… OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc. and Lomond Therapeutics Holdings, Inc., each a public biopharmaceutical company, as well as several private companies. Dr. Gordon previously served on the boards of directors of several public companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 404 ---
Rallybio CorpAdicet Bio, Inc.·S-4/A - Registration statement (business combination, amendment)·Q4 26·2 Oct
… imovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc. …
ADARx Pharmaceuticals, Inc.Adicet Bio, Inc.·424B4 - Prospectus filing (Rule 424(b)(4))·Q3 26·25 Sep
… rivate biotechnology company, where he also served on its board of directors. From May 2019 to September 2020, Dr. Singhal served as the President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., or Adicet Bio, where he led the then-private biotechnology company to its first oncology investigational new drug application submission and its merger with resTOR bio, Inc., which resulted in Adicet Bio becoming a …
Werewolf Therapeutics, Inc.Adicet Bio, Inc.·S-4 - Registration statement (business combination)·Q3 26·22 Sep
… since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly-traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. f …
ADARx Pharmaceuticals, Inc.Adicet Bio, Inc.·S-1/A - Registration statement (general form, amendment)·Q3 26·21 Sep

Key Stats

Trading

Px/Chg 1D$6.50 / -2.11%

Prev Close$9.59

% of 52Wk H55.79%

Avg Volume114.98K

Beta1.94

Mkt Cap60.76M

FD Mkt Cap90.96M

Float

Shrs Out/Float9.35M / 8.20M

Short Float0.06%

Days to Cover5.25

Stock Repurchased$0.00

Current Valuation

EV38.42M

EV/EBITDA-0.37

EV/Sales0.00

P/B0.43

P/S0.00

FCF Yield-35.43%

ROE-14.45%

ROA-11.95%

Current Ratio7.65

Dividend

Cash$0.00

Yield0.89%

Yield (TTM)0.89%

Estimates

P/E-0.56

Est P/EN/A

Est EPSN/A

Est PEGN/A

Valuation

Metric	5Yr Avg	May '23	May '24	May '25	May '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-1.93	-3.92	-0.43	-0.50	-1.80	-3.01
Price / Sales	2.19	10.95	0.00	0.00	0.00	0.00
Price / Book Value	0.48	0.94	0.36	0.31	0.34	0.44
Price / Free Cash Flow	-2.23	-4.45	-0.63	-0.63	-2.62	-2.83
ENTERPRISE VALUE METRICS
Enterprise Value	9.7	37.0	-76.8	19.2	30.6	38.6
Enterprise Value / Sales	0.30	1.48	0.00	0.00	0.00	0.00
Enterprise Value / EBITDA	-0.66	-0.57	0.56	-0.17	-1.05	-2.04
Enterprise Value / EBIT	-0.61	-0.53	0.54	-0.16	-1.00	-1.91

Financials

Full Financials

Millions USD	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	—	9.7	25.0	-	-	-
Gross Income	—	9.7	25.0	-	-	-6.4
EBITDA	16.3%	-60.4	-64.7	-136.5	-110.7	-110.4
EBIT	17.2%	-61.9	-69.7	-142.6	-117.1	-116.8
Net Income	17.2%	-62.0	-69.8	-142.7	-117.1	-116.8
EPS (Diluted)	-14.7%	-32.00	-27.20	-52.96	-21.28	-16.95
BALANCE SHEET
Cash & ST Inv	-13.1%	277.5	257.7	159.7	176.3	158.5
Total Assets	-13.2%	338.9	330.7	207.3	220.2	192.4
Total Liabilities	-1.9%	35.8	38.4	37.1	33.6	33.1
Total Shareholder Equity	-14.9%	303.1	292.3	170.2	186.6	159.2
CASH FLOW
Net Operating Cash Flow	16.9%	-51.1	-44.8	-93.7	-92.4	-95.2
Cap Ex	-39.6%	-13.0	-16.8	-4.5	-1.1	-1.7
Free Cash Flow	10.9%	-64.1	-61.5	-98.2	-93.5	-97.0

Enterprise Value Bridge

Millions USD		23 Oct '26
Price (As of 23 Oct '26)		4.02
Basic Shares		9.35
Market Cap		37.6
Diluted Shares		10.74
Fully Diluted Shares Outstanding		10.74
Fully Diluted Market Cap		43.2
+Consolidated Debt		13.9
−In-the-Money Convertible Debt		—
+Capital Leases		13.9
+Operating Leases		—
−Cash & Equivalents		-36.2
−Short-term Investments		-101.3
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		15.2

Segment data

Revenue

by Products and services

Human Health49%
Performance Chemicals26%
Pharmaceutical Ingredients25%

Revenue

by Geography

United States76%
Germany12%
France6%
Asia Pacific5%
Netherlands2%

Adicet Bio, Inc.(ACET US)